Skip to content

comparison of drugs for shivering after spinal anaesthesia

comparative evaluation of dexmedetomidine versus nalbuphine for control of post spinal shivering - DEX NAL

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/12/048178
Enrollment
60
Registered
2022-12-16
Start date
Unknown
Completion date
Unknown
Last updated
2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: O- Medical and Surgical

Interventions

Intervention1: dexmedetomidine: 1 mcg/kg, intravenous for 30 minutes ,control of shivering Control Intervention1: nalbuphine: 0.05 mg/kg, intravenous, for 30 minutes control of shivering

Sponsors

dr d y patil vidyapeeth pimpri pune
Lead Sponsor
dr d y patil vidyapeeth pimpri pune
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: ASA grade I & II. 2. Age between 18 and 60 years of either sex. 3. Patients undergoing surgeries under spinal anaesthesia. 4. Haemodynamically stable patients with all routine investigations within normal limits. 5. Patients who are not on any cardiac related drugs 5. Availability of an informed consent.

Exclusion criteria

Exclusion criteria: . Patient refusal. 2. Patients with ASA physical status III or more. 3. Patients receiving sedative/ hypnotic agents. 4. Patients with uncontrolled hypertension, hyperthyroidism, hypothyroidism, psychiatric disorders, severe diabetes or autonomic neuropathy. 5. Patients with history of cardiac, respiratory, renal or hepatic diseases. 6. Patients with history of alcohol or drug abuse. 7. Patients who have a history of allergy to any of the test drugs. 8. Contraindications to spinal anaesthesia (coagulation disorder, infection at puncture site, raised intracranial tension, pre-existing neurological deficit in lower extremities or any spine deformity). 9. Initial body temperature >38°C or

Design outcomes

Primary

MeasureTime frame
control of shiveringTimepoint: baseline, 0, 1, 2, 5, 10, 15, 20 minutes

Secondary

MeasureTime frame
control of shiveringTimepoint: baseline, 0, 1, 2, 5, 10, 15, 20 minutes after giving the drug

Countries

India

Contacts

Public Contactsonalika tudimilla

dr. d.. y. patil vidyapeeth

sona3668@hotmail.com9676989293

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026